| scholarly article | Q13442814 |
| P356 | DOI | 10.7164/ANTIBIOTICS.37.1231 |
| P698 | PubMed publication ID | 6501094 |
| P2093 | author name string | C Vézina | |
| S N Sehgal | |||
| C P Eng | |||
| P2860 | cites work | Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. | Q105219584 |
| P433 | issue | 10 | |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 1231-1237 | |
| P577 | publication date | 1984-10-01 | |
| P1433 | published in | The Journal of Antibiotics | Q7743552 |
| P1476 | title | Activity of rapamycin (AY-22,989) against transplanted tumors | |
| P478 | volume | 37 |
| Q33330310 | A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials |
| Q44462149 | A wholly nutritional 'multifocal angiostatic therapy' for control of disseminated cancer |
| Q89762212 | Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma |
| Q40259870 | Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma |
| Q47151332 | Amino acid and small GTPase regulation of mTORC1. |
| Q38822715 | An overview of rapamycin: from discovery to future perspectives |
| Q54642065 | Are we missing the mTOR target in breast cancer? |
| Q60395558 | Chemistry and Pharmacology of Rapamycin and Its Derivatives |
| Q37871915 | Clinical activity of mammalian target of rapamycin inhibitors in solid tumors |
| Q35038759 | Clinical development of mammalian target of rapamycin inhibitors |
| Q90116614 | Cyclodipeptides from Pseudomonas aeruginosa modulate the maize (Zea mays L.) root system and promote S6 ribosomal protein kinase activation |
| Q64111733 | Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients |
| Q48196930 | Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse |
| Q58548409 | Emerging Interventions for the Elderly - The Promise of Regenerative Medicine |
| Q29615120 | Exploiting the PI3K/AKT pathway for cancer drug discovery |
| Q38065993 | Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands |
| Q40136744 | Historical perspective of living donor liver transplantation |
| Q35636781 | Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors |
| Q72753027 | Immunosuppressive agents |
| Q45283332 | Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy |
| Q43619915 | Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors |
| Q34302032 | Inhibition of liver, kidney, and intestine regeneration by rapamycin |
| Q34608329 | Inhibition of mTOR in kidney cancer |
| Q44569617 | Involvement of the Akt/mTOR pathway on EGF-induced cell transformation |
| Q35096214 | Issues and progress with protein kinase inhibitors for cancer treatment |
| Q33942901 | Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo |
| Q37149427 | Malignancy in kidney transplant recipients |
| Q37866136 | Mammalian target of rapamycin as a target in hematological malignancies |
| Q35653049 | Mammalian target of rapamycin inhibition as therapy for hematologic malignancies |
| Q36778676 | Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies. |
| Q64075806 | Mechanistic Target of Rapamycin Pathway in Epileptic Disorders |
| Q38133765 | Microbial natural products: molecular blueprints for antitumor drugs. |
| Q35881144 | Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions |
| Q64085474 | Molecular Mechanisms Controlled by mTOR in Male Reproductive System |
| Q33665207 | Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy |
| Q24806542 | New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists |
| Q36693690 | Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer |
| Q47159555 | Oncogene-Driven Metabolic Alterations in Cancer |
| Q47134039 | Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities |
| Q41841053 | Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. |
| Q35542196 | Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients |
| Q37348173 | Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. |
| Q42807577 | Potential of mTOR inhibitors as therapeutic agents in hematological malignancies |
| Q35064974 | Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease |
| Q28286510 | Rapalogs and mTOR inhibitors as anti-aging therapeutics |
| Q57362835 | Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression |
| Q44934221 | Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas |
| Q64891783 | Rapamycin for immunosuppression in organ allografting. |
| Q36052440 | Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation |
| Q41571950 | Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma |
| Q43873032 | Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor |
| Q41970819 | Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract |
| Q27934061 | Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein |
| Q74685389 | Rapamycin's effect on vasomotion in the rat |
| Q37000488 | Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. |
| Q57245409 | Recent advances in immunosuppression |
| Q37824477 | Role of mTOR signaling in tumor cell motility, invasion and metastasis |
| Q43917035 | Secondary metabolism in simulated microgravity |
| Q36667245 | Sirolimus reduces polycystic liver volume in ADPKD patients |
| Q35125746 | Sirolimus: its discovery, biological properties, and mechanism of action |
| Q89479857 | TOR signaling in plants: conservation and innovation |
| Q50317234 | TPT1 (tumor protein, translationally-controlled 1) negatively regulates autophagy through the BECN1 interactome and an MTORC1-mediated pathway |
| Q37655450 | Targeted therapy for sarcomas |
| Q36742629 | Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations |
| Q34129360 | Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma |
| Q35125788 | Ten years of sirolimus therapy in orthotopic liver transplant recipients |
| Q47999511 | The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway |
| Q35125756 | The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation |
| Q29614242 | The TOR pathway: a target for cancer therapy |
| Q41663514 | The TORC2-Dependent Signaling Network in the Yeast Saccharomyces cerevisiae. |
| Q34116818 | The complexes of mammalian target of rapamycin. |
| Q35223564 | The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer |
| Q83446861 | The incidence of cancer and potential role of sirolimus immunosuppression conversion on mortality among a single-center renal transplantation cohort of 1,816 patients |
| Q36730484 | The inhibitory effect of rapamycin on the oval cell response and development of preneoplastic foci in the rat. |
| Q35850028 | The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL |
| Q24627306 | The mTOR signalling pathway in human cancer |
| Q28478235 | The physiology and pathophysiology of rapamycin resistance: implications for cancer |
| Q37791408 | The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation |
| Q34293622 | The rapamycin-sensitive signal transduction pathway as a target for cancer therapy |
| Q89634997 | The role of RICTOR amplification in targeted therapy and drug resistance |
| Q36858227 | The role of mTOR inhibitors for treatment of sarcomas |
| Q36191321 | Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus |
| Q47159548 | Twenty-five years of mTOR: Uncovering the link from nutrients to growth. |
| Q24607170 | Updates of mTOR inhibitors |
| Q35889533 | Virtual Screening and Experimental Validation Identify Novel Inhibitors of the Plasmodium falciparum Atg8-Atg3 Protein-Protein Interaction. |
| Q37385781 | mTOR Inhibition: From Aging to Autism and Beyond. |
| Q38747508 | mTOR Signaling in Growth, Metabolism, and Disease. |
| Q29617779 | mTOR and cancer: insights into a complex relationship |
| Q90854370 | mTOR as a central hub of nutrient signalling and cell growth |
| Q92643974 | mTOR at the nexus of nutrition, growth, ageing and disease |
| Q37743486 | mTOR function and therapeutic targeting in breast cancer |
| Q89523557 | mTOR in Lung Neoplasms |
| Q24612127 | mTOR inhibitors in advanced renal cell carcinoma |
| Q35848196 | mTOR regulates cell survival after etoposide treatment in primary AML cells |
| Q37763231 | mTOR signaling in cancer cell motility and tumor metastasis |
| Q48293926 | mTOR signaling in stem and progenitor cells |
| Q36919646 | mTOR signalling in human cancer |
Search more.